RESEARCH ARTICLE

International Journal of Responsible Artificial Intelligence

AI-Enhanced Management of Complicated Peptic Ulcer Disease: Integrating Proton Pump Inhibitors, Endoscopy, and Surgery

Suman Thapa[1], **Anjali Gurung**[2] and **Kiran Poudel**[3]

Full list of author information is available at the end of the article
*NEURALSLATE†

Abstract

Complicated peptic ulcer disease (PUD), characterized by bleeding, perforation, or obstruction, presents significant challenges in clinical management. The integration of artificial intelligence (AI) into the diagnostic and therapeutic workflow has shown promising potential to enhance patient outcomes. This study examines the role of AI in optimizing the use of proton pump inhibitors (PPIs), endoscopic procedures, and surgical interventions in the management of complicated PUD. AI-powered predictive models can assist in early identification of high-risk patients, enabling timely initiation of PPIs to minimize ulcer progression and bleeding risk. Additionally, AI-enhanced imaging technologies improve diagnostic accuracy during endoscopy by identifying subtle mucosal changes and predicting the severit]y of ulcers. These advancements facilitate targeted interventions, such as endoscopic hemostasis for bleeding ulcers or stent placement in cases of obstruction. In surgical management, AI aids in preoperative planning by assessing patient-specific risks and predicting postoperative outcomes. Furthermore, AI-driven decision-support systems can guide clinicians in choosing between minimally invasive and open surgical approaches, optimizing patient recovery. This paper discusses the integration of these AI tools into clinical practice, their implications for healthcare providers, and potential barriers to widespread adoption. By streamlining decision-making processes and enhancing precision in treatment strategies, AI has the potential to transform the management of complicated PUD. However, ethical considerations, data privacy concerns, and the need for rigorous validation studies remain challenges to be addressed. This review concludes with recommendations for future research to refine AI applications and ensure equitable access to advanced technologies, aiming to improve outcomes for patients with complicated PUD globally.

Keywords: AI; endoscopy; cryptographic protocols; peptic ulcer disease; proton pump inhibitors; surgical management

1 Introduction

Peptic ulcer disease (PUD) is a prevalent gastrointestinal condition characterized by mucosal erosion, primarily within the stomach and proximal duodenum, that arises from an imbalance between protective mucosal defenses and damaging factors. These damaging factors include elevated gastric acid secretion, infection with *Helicobacter pylori*, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs).



Figure 1 Peptic ulcer treatment: pharmacology of drugs

The clinical spectrum of PUD varies widely, ranging from asymptomatic presentations to severe complications such as bleeding, perforation, and gastric outlet obstruction. These complications pose significant clinical challenges and contribute to considerable morbidity, mortality, and healthcare costs on a global scale. Advances in pharmacological and interventional therapies have improved the prognosis for many patients; however, the effective management of complicated PUD often necessitates a multidisciplinary approach to optimize clinical outcomes.

One of the most significant advances in contemporary medicine has been the application of artificial intelligence (AI) to a wide range of clinical problems. AI encompasses a variety of technologies, such as machine learning (ML), deep learning, and natural language processing, which have the capability to analyze vast datasets, discern patterns, and predict outcomes with remarkable precision. These technologies are now being applied to numerous areas of clinical practice, including diagnostics, therapeutic planning, and risk stratification. In the context of complicated PUD, AI has the potential to address critical challenges, including early diagnosis, real-time decision-making, and the personalization of treatment strategies. The ability of AI algorithms to synthesize and interpret complex clinical data can support clinicians in making timely, evidence-based decisions, thereby mitigating the risks associated with delayed or suboptimal management.

Proton pump inhibitors (PPIs), endoscopic interventions, and surgical procedures form the cornerstone of PUD management, particularly in complicated cases. PPIs remain the first-line therapy for acid suppression, effectively promoting ulcer healing and reducing the risk of recurrence. Endoscopic techniques, including hemostasis for bleeding ulcers, are essential for both diagnostic and therapeutic purposes. Surgical intervention is reserved for refractory cases or complications such as perforation and obstruction that cannot be managed conservatively. The integration of AI into these therapeutic domains holds promise for improving clinical outcomes by enhancing the precision, efficiency, and timeliness of interventions. For example, AI-driven endoscopic systems can aid in lesion detection and characterization, while predictive algorithms can stratify patients by their likelihood of response to pharmacologic or surgical therapies.

In this paper, we explore the intersection of AI and the clinical management of complicated PUD, with a focus on how AI-based tools are enhancing the precision and efficacy of therapeutic interventions. We begin by discussing the role of AI in optimizing the use of PPIs, examining how machine learning algorithms can predict treatment response based on patient-specific variables. We then address AI applications in endoscopy, including real-time lesion detection and risk stratification for rebleeding. Finally, we review the use of AI in surgical decision-making, particularly in predicting postoperative outcomes and identifying candidates for minimally invasive techniques. In addition, we critically evaluate the challenges and limitations associated with the implementation of AI technologies in routine clinical practice, emphasizing the importance of ethical considerations, data standardization, and validation in diverse patient populations. Through this discussion, we aim to highlight the transformative potential of AI in advancing the management of complicated PUD and to underscore the need for continued research and multidisciplinary collaboration in this evolving field.

To provide a comprehensive understanding of the subject, we also include data and projections regarding the current burden of PUD-related complications, alongside the potential impact of AI integration in reducing this burden. Table 1 provides an overview of the global prevalence, mortality, and healthcare costs associated with complicated PUD. Meanwhile, Table 2 summarizes key AI advancements and their applications across the therapeutic spectrum of complicated PUD, illustrating their relevance to clinical practice.

The remainder of this paper is structured as follows: Section 2 delves into the pathophysiological mechanisms underlying PUD and the clinical challenges posed by its complications. Section 3 discusses AI's role in enhancing pharmacological therapies, specifically PPIs, and its application to endoscopic interventions. Section 4 examines AI-driven approaches to surgical management, and Section 5 critically evaluates the ethical, logistical, and practical barriers to the implementation of AI in clinical practice. Finally, Section 6 provides conclusions and outlines future research directions for the integration of AI into the management of complicated PUD.

Table 1 Global Burden of Complicated Peptic Ulcer Disease (PUD)

Parameter	Global Estimate	Implications
Prevalence of Complicated PUD	Approximately 4 million cases annually	Indicates a significant public health burden requiring resource-intensive management
Mortality Rate	5–10% in patients with complications	Highlights the importance of timely and effective therapeutic interventions
Healthcare Costs	Over $8 billion annually in direct and indirect costs	Reflects the economic impact of PUD complications, including hospitalization and surgical expenses

Table 2 Key AI Advancements in the Management of Complicated PUD

AI Application	Domain of Use	Clinical Impact
Machine Learning for PPI Response Prediction	Pharmacotherapy	Enables personalized treatment by predicting patient-specific responses to acid suppression therapy
AI-Assisted Endoscopy	Diagnostic and Therapeutic Endoscopy	Improves accuracy in lesion detection, bleeding source localization, and risk stratification for rebleeding
Predictive Analytics for Surgical Outcomes	Surgical Decision-Making	Assists in identifying high-risk patients and tailoring surgical approaches, such as minimally invasive techniques

2 AI-Driven Optimization of Proton Pump Inhibitor Therapy

Proton pump inhibitors (PPIs) are integral to the therapeutic management of peptic ulcer disease (PUD), primarily due to their ability to inhibit gastric acid secretion effectively. This inhibition facilitates the healing of gastric and duodenal mucosal lesions, offering symptomatic relief and reducing the risk of severe complications such as gastrointestinal (GI) bleeding or perforation. In patients with complicated PUD, particularly those presenting with bleeding ulcers, the early administration of PPIs can stabilize the clinical condition and mitigate the risk of recurrent bleeding. However, identifying patients at heightened risk of such complications remains a persistent challenge, often leading to delays in initiating appropriate therapy or suboptimal dosing strategies. This issue has profound implications for morbidity, mortality, and healthcare resource utilization.

Artificial intelligence (AI) has emerged as a powerful tool to optimize PPI therapy through predictive modeling, personalized treatment strategies, and enhanced patient engagement. Recent advancements in machine learning (ML) have enabled the development of predictive algorithms that leverage large-scale patient data, such as electronic health records (EHRs). These algorithms analyze complex interactions among clinical variables, including patient demographics, comorbidities, medication histories, laboratory parameters, and endoscopic findings, to predict individual patient risk profiles. For instance, models trained on large EHR datasets can stratify patients based on their likelihood of ulcer-related bleeding or perforation, allowing for targeted interventions. An example of such an approach is the use of AI to identify patients on chronic non-steroidal anti-inflammatory drug (NSAID) therapy who are at high risk of developing NSAID-induced ulcers. These patients may benefit significantly from prophylactic PPI therapy, a strategy shown to reduce the incidence of ulceration and its associated complications.

The implementation of AI-driven optimization extends beyond risk stratification. One significant area of advancement is the use of digital health platforms to improve adherence to PPI regimens. Poor adherence to PPI therapy is a well-documented problem, particularly in the context of long-term treatment for chronic conditions such as gastroesophageal reflux disease (GERD) and PUD prophylaxis. Mobile applications and wearable devices equipped with AI algorithms have demonstrated potential in monitoring adherence, providing personalized reminders, and identifying behavioral patterns associated with missed doses. For instance, AI-driven applications can analyze patient interactions with reminders and assess adherence trends, subsequently recommending tailored interventions to overcome identified barriers, such as simplifying dosing schedules or addressing misconceptions about side effects. By integrating these digital tools into routine clinical workflows, healthcare providers can enhance therapeutic adherence and ensure that patients derive the full benefits of PPI therapy.

Furthermore, AI has a critical role in guiding dose optimization and therapy duration. While PPIs are generally considered safe and well-tolerated, prolonged or inappropriate use can lead to adverse outcomes, such as increased risks of enteric infections, vitamin and mineral deficiencies, and potential renal dysfunction. AI algorithms can assist clinicians in determining the optimal duration of therapy by continuously assessing patient response to treatment through EHR data, laboratory tests, and symptom tracking. Such dynamic feedback mechanisms enable the early identification of patients who can transition to lower doses or discontinue therapy, minimizing unnecessary exposure to PPIs.

To illustrate the potential of AI-driven PPI therapy optimization, consider the following hypothetical dataset analysis. Table 3 presents an example of variables commonly used by AI models to predict ulcer complications, while Table 4 highlights AI-assisted interventions designed to improve patient adherence to PPI therapy.

Table 3 Key Predictive Factors for Ulcer Complications in AI Models

Variable	Description and Relevance
Age	Advanced age is a significant risk factor for peptic ulcer complications, including bleeding and perforation, due to age-related changes in mucosal defense mechanisms.
Comorbidities	Conditions such as chronic kidney disease, diabetes, and cardiovascular disease increase vulnerability to GI complications.
Medication Use	Chronic use of NSAIDs, corticosteroids, and antiplatelet agents (e.g., aspirin) exacerbates the risk of ulceration.
Laboratory Parameters	Indicators such as hemoglobin, platelet count, and serum albumin are predictive of bleeding risk and overall nutritional status.
Endoscopic Findings	Characteristics such as ulcer size, location, and stigmata of recent hemorrhage provide valuable prognostic information.

Table 4 AI-Assisted Interventions for Improving PPI Adherence

Intervention	AI-Driven Implementation
Personalized Reminders	Mobile applications send reminders tailored to patient preferences, such as text alerts or app notifications at optimal times.
Behavioral Analytics	AI analyzes adherence patterns to identify patients at risk of noncompliance and suggests targeted interventions.
Education Modules	Interactive AI-powered platforms provide tailored educational content addressing patient-specific concerns, such as side effect management.
Feedback Loops	Continuous monitoring of patient responses to interventions allows AI systems to refine strategies in real time.

Despite the promising applications of AI in optimizing PPI therapy, several challenges must be addressed to maximize its utility in clinical practice. The accuracy of AI-based predictive models is contingent upon the quality, volume, and diversity of training datasets. For example, datasets that disproportionately represent certain populations may fail to generalize across diverse patient groups, introducing the potential for algorithmic bias. This issue is particularly relevant in PUD, where variations in genetic, dietary, and environmental factors influence disease prevalence and treatment response. Addressing these limitations requires efforts to standardize data collection and promote the inclusion of underrepresented populations in AI model development.

Another critical challenge is the ethical and legal considerations surrounding the use of patient data in AI systems. The integration of AI into healthcare necessitates compliance with data privacy regulations, such as the General Data Protection Regulation (GDPR) in Europe or the Health Insurance Portability and Accountability Act (HIPAA) in the United States. Balancing the need for extensive data to train robust models with the imperative to safeguard patient privacy is a delicate task that requires ongoing innovation in data anonymization and secure storage techniques.

Finally, the implementation of AI tools in clinical settings depends on the acceptance and confidence of healthcare providers. Training programs aimed at improving clinician familiarity with AI technologies and their applications in PPI therapy are essential to overcome resistance to adoption. Transparent reporting of AI model performance, including metrics such as sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC), can further build trust among clinicians and patients alike.

the integration of AI into PPI therapy offers an unprecedented opportunity to enhance the management of peptic ulcer disease. By enabling precise risk stratification, improving adherence, and guiding therapy optimization, AI-driven approaches have the potential to transform clinical outcomes while addressing inefficiencies in current practice. However, the success of these innovations depends on addressing challenges related to data quality, privacy, and provider acceptance, ensuring that AI technologies are both effective and equitable in their application.

3 Enhancing Endoscopic Diagnosis and Treatment with AI

Endoscopy remains an indispensable tool in the diagnosis and treatment of complicated peptic ulcer disease (PUD), offering direct visualization of ulcerative lesions, as well as enabling therapeutic interventions for complications such as bleeding, perforation, or obstruction. However, the outcomes of endoscopic procedures often depend on the proficiency and experience of the operator, resulting in variability in diagnostic accuracy and therapeutic success. Artificial intelligence (AI) has emerged as a transformative technology in the field of gastroenterology, with the potential to standardize endoscopic procedures, enhance diagnostic precision, and optimize therapeutic interventions for complicated PUD. By integrating advanced computational methodologies, AI-powered systems hold promise to overcome many of the limitations associated with conventional endoscopic practices.

One of the most groundbreaking applications of AI in endoscopy is the development and deployment of computer-aided detection (CAD) systems. These systems utilize deep learning algorithms, particularly convolutional neural networks (CNNs), to process endoscopic images and identify abnormal features, such as bleeding sites, perforations, or early neoplastic changes. By analyzing millions of labeled datasets, these algorithms achieve remarkable sensitivity and specificity in detecting subtle mucosal abnormalities that might evade the human eye. For example, studies have shown that CAD systems can successfully distinguish between benign and malignant gastric ulcers based on visual characteristics, significantly improving the early detection of gastric cancer in patients presenting with complicated PUD. The real-time application of CAD allows the system to provide visual annotations or highlight regions of interest during endoscopic procedures, thus acting as a "second observer" to assist endoscopists in identifying critical lesions. Furthermore, AI has proven particularly effective in assessing the severity of ulcers by analyzing features such as ulcer size, depth, and associated vascular changes. This ability to quantify ulcer severity in a reproducible manner enhances clinical decision-making, particularly when determining the need for aggressive interventions or prolonged pharmacologic therapy.

In the therapeutic domain, AI demonstrates substantial utility in guiding endoscopic interventions. For instance, machine learning models have been developed to predict the risk of rebleeding following endoscopic hemostasis. These predictive models analyze a wide range of patient-specific variables, including hemodynamic stability, comorbidities, ulcer characteristics, and laboratory findings, to stratify patients into high-risk and low-risk categories. This enables clinicians to personalize follow-up strategies, such as scheduling repeat endoscopies, initiating second-look procedures, or prescribing adjunctive pharmacotherapy to prevent recurrent bleeding. Additionally, AI algorithms can assist in selecting the most appropriate endoscopic devices and techniques based on patient-specific needs. For example, AI-driven platforms can recommend the use of hemostatic clips for ulcers with visible vessels, thermal coagulation for diffuse bleeding, or stent placement in cases of obstruction, optimizing therapeutic efficacy while minimizing complications.

The integration of AI into endoscopic practice is not limited to clinical care but extends to the training and education of endoscopists. Traditional methods of training rely on supervised practice under the guidance of experienced clinicians, which may not adequately prepare trainees for the diversity of scenarios encountered in real-world practice. AI-enabled virtual reality (VR) simulators have emerged as powerful tools for enhancing the educational experience. These simulators create realistic, high-fidelity scenarios that mimic the challenges of diagnostic and therapeutic endoscopy. Trainees can practice navigating complex cases, such as identifying obscure bleeding sources or managing difficult-to-access lesions, while receiving real-time feedback from AI algorithms. The AI system evaluates performance metrics such as scope handling, lesion detection rates, and procedural efficiency, providing actionable insights to improve trainee skills. Moreover, by standardizing the assessment of endoscopic competencies, AI-driven training programs reduce variability in operator proficiency and promote consistent quality of care across different healthcare settings.

The implementation of AI in endoscopy is not without challenges. One major hurdle is the need for rigorous validation of CAD systems across diverse patient populations. Many current algorithms are trained on datasets derived from specific demographic groups or healthcare settings, limiting their generalizability to broader populations. This underscores the importance of conducting large-scale, multicenter trials to evaluate the performance of AI systems in real-world settings and to refine algorithms for diverse clinical scenarios. Another significant barrier is the high cost associated with developing and deploying AI technologies. From the computational infrastructure required to train deep learning models to the integration of AI systems into existing endoscopic workflows, the financial burden can be prohibitive for many healthcare institutions, particularly in resource-limited settings. Addressing these cost constraints is crucial to ensure equitable access to AI-enhanced endoscopic tools. Furthermore, ethical considerations, such as data privacy and algorithm transparency, must be addressed to foster trust among clinicians and patients in the use of AI for medical decision-making.

Despite these challenges, the potential benefits of AI in endoscopy far outweigh its limitations. By enhancing diagnostic accuracy, guiding therapeutic interventions, and standardizing training, AI has the potential to revolutionize the management of complicated PUD. The following tables summarize key advancements in AI applications for diagnostic and therapeutic endoscopy and outline the benefits and limitations of AI integration in endoscopic practice.

Table 5 Applications of AI in Diagnostic Endoscopy for Complicated PUD

AI Application	Description and Impact
Computer-aided detection (CAD) systems	Use deep learning algorithms to analyze endoscopic images and detect abnormalities such as bleeding, perforations, and malignant transformations. Improves diagnostic accuracy and facilitates early detection of complications.
Real-time lesion annotation	Provides visual highlights of suspicious areas during procedures, acting as a second observer to assist endoscopists in identifying subtle mucosal changes.
Ulcer severity assessment	Quantifies ulcer characteristics such as size, depth, and vascular involvement, aiding in clinical decision-making for treatment planning.

Table 6 Applications of AI in Therapeutic Endoscopy for Complicated PUD

AI Application	Description and Impact
Predictive models for rebleeding	Analyzes patient-specific variables to estimate the likelihood of rebleeding after endoscopic hemostasis, enabling personalized follow-up strategies.
Device and technique selection	Recommends appropriate therapeutic modalities such as hemostatic clips, thermal probes, or stents based on procedural goals and patient factors.
AI-driven training simulators	Provides realistic virtual scenarios for trainee endoscopists, offering performance feedback and standardizing skill assessment to ensure consistent care.

the integration of AI into endoscopic diagnosis and treatment represents a paradigm shift in the management of complicated PUD. By leveraging the capabilities of deep learning and predictive analytics, AI has the potential to enhance every aspect of endoscopic practice, from improving diagnostic accuracy and therapeutic precision to advancing medical education and training. As the field continues to evolve, addressing challenges such as validation, cost, and ethical considerations will be critical to realizing the full potential of AI in gastroenterology. With ongoing innovation and collaboration among clinicians, researchers, and technologists, AI-enhanced endoscopy is poised to become a cornerstone of modern gastrointestinal care.

4 AI in Surgical Decision-Making and Planning

Surgical intervention represents a critical therapeutic avenue for patients with complicated peptic ulcer disease (PUD) who fail to respond to medical or endoscopic treatments. The decision-making process surrounding surgical intervention requires a meticulous assessment of numerous patient-specific factors, including the severity of the disease, comorbidities, and the feasibility of different surgical approaches. Advances in artificial intelligence (AI) have introduced the potential to significantly transform surgical planning and decision-making processes, enhancing both the precision of operative strategies and postoperative outcomes for patients with complicated PUD.

One of the most impactful applications of AI in surgical planning lies in predictive analytics. Machine learning algorithms, particularly those employing supervised learning methodologies, are capable of analyzing vast datasets comprising preoperative imaging, laboratory parameters, and detailed clinical histories. These AI systems can stratify patients based on surgical risk profiles, identifying individuals at elevated risk for complications such as postoperative bleeding, infection, or anastomotic leakage. For instance, AI tools utilizing neural networks can integrate high-dimensional data from contrast-enhanced CT scans and other diagnostic imaging to predict the likelihood of perforation recurrence or poor wound healing. By enabling more granular risk stratification, these predictive models empower surgeons to devise tailored preoperative strategies, such as optimizing the patient's nutritional and hemodynamic status or addressing modifiable risk factors before surgery. Additionally, AI can facilitate the selection of candidates for minimally invasive procedures, such as laparoscopic repair of perforated ulcers, which are generally associated with lower rates of postoperative pain, faster recovery, and decreased morbidity.

AI also plays an increasingly significant role intraoperatively, particularly in enhancing the precision and efficiency of surgical interventions. Augmented reality (AR) systems driven by AI algorithms can superimpose preoperative imaging data directly onto the operative field, providing real-time guidance during surgery. These technologies are particularly beneficial in managing perforated PUD, where the identification of the perforation site and surrounding tissue integrity is paramount. For example, AI-powered AR systems can delineate areas of necrosis or ischemia, enabling surgeons to excise only the affected tissue while preserving as much healthy anatomy as possible. Moreover, robotic surgical platforms equipped with AI-driven feedback mechanisms allow for superior dexterity and precision, reducing the risk of iatrogenic injury during complex procedures.

Postoperative care represents another domain where AI-driven innovations can have transformative effects. AI systems integrated with wearable technologies, such as biosensors, can continuously monitor patients for early signs of complications, including infection, ileus, or delayed gastric emptying. These platforms employ machine learning algorithms to analyze trends in vital signs, laboratory values, and other physiological parameters, issuing alerts to clinicians when deviations from expected recovery trajectories occur. For instance, a drop in oxygen saturation or a sudden increase in heart rate variability might prompt earlier intervention, such as imaging studies or adjustments to antibiotic regimens. Natural language processing (NLP) tools further complement these efforts by analyzing unstructured data within electronic health records (EHRs), such as operative notes, discharge summaries, and follow-up documentation, to identify patterns associated with suboptimal outcomes or areas for process improvement. Over time, the integration of such AI tools into postoperative workflows can contribute to the development of evidence-based best practices, ultimately enhancing the overall quality of surgical care.

Despite these promising advancements, several challenges hinder the widespread adoption of AI in surgical decision-making and planning. The validation of predictive models is a complex and resource-intensive process, requiring large, diverse datasets to ensure their generalizability and reliability. Additionally, the integration of AI technologies into clinical practice often entails substantial upfront costs, which may be prohibitive for resource-limited settings. Ethical concerns related to data privacy, algorithmic bias, and the interpretability of AI decisions further complicate implementation. Addressing these barriers necessitates collaboration among clinicians, data scientists, policymakers, and industry stakeholders to ensure the development of AI tools that are not only effective but also equitable and accessible.

To illustrate the versatility and potential of AI applications in surgical planning, we present two tables. The first table summarizes various AI models currently employed in preoperative risk stratification and their corresponding outcomes. The second table outlines the benefits and limitations of AI-driven intraoperative and postoperative technologies in the management of complicated PUD.

Table 7 AI Models in Preoperative Risk Stratification

AI Model	Data Inputs	Predicted Outcomes
Random Forest Algorithms	Imaging data, laboratory results, clinical history	Identification of high-risk patients for complications such as bleeding or infection
Convolutional Neural Networks (CNNs)	Contrast-enhanced CT scans	Prediction of ulcer perforation size and tissue necrosis
Support Vector Machines (SVMs)	Hemodynamic parameters, nutritional status	Risk of poor wound healing and anastomotic leakage
Gradient Boosting Models	Preoperative endoscopic findings, inflammatory markers	Probability of prolonged hospital stay

Table 8 Applications of AI in Intraoperative and Postoperative Management of Complicated PUD

Domain	AI-Driven Technology	Advantages and Limitations
Intraoperative Guidance	AI-powered augmented reality systems	Enhanced anatomical visualization; limited by high cost and learning curve
Robotic Surgery	Machine learning-assisted robotic platforms	Increased precision and reduced complications; dependent on operator expertise
Postoperative Monitoring	AI-integrated wearable sensors	Early detection of complications; requires robust data interpretation frameworks
Natural Language Processing (NLP)	Analysis of EHR data and surgical notes	Identification of care trends and optimization of future strategies; potential issues with data standardization

the integration of AI into surgical decision-making and planning for patients with complicated PUD holds great promise for advancing patient care. By leveraging the power of predictive analytics, real-time intraoperative guidance, and AI-driven postoperative monitoring, clinicians can optimize surgical outcomes and minimize complications. Nevertheless, the full potential of these technologies will only be realized through concerted efforts to address the challenges of validation, cost, and equity in implementation. Continued research and interdisciplinary collaboration will be pivotal in ensuring that AI becomes a cornerstone of modern surgical practice.

5 Conclusion

The integration of artificial intelligence (AI) into the management of complicated peptic ulcer disease (PUD) signifies a transformative evolution in the realm of gastrointestinal medicine. AI-driven innovations are revolutionizing traditional approaches to diagnosis, treatment, and postoperative care, paving the way for a new era of precision medicine. By augmenting the efficacy of proton pump inhibitor (PPI) therapy, optimizing endoscopic techniques, and refining surgical interventions, AI demonstrates unparalleled potential to improve patient outcomes and streamline clinical workflows. From predictive algorithms that identify high-risk patients to computer-aided detection (CAD) systems that enhance diagnostic accuracy, the applications of AI extend across all phases of PUD management. Real-time guidance tools, enabled by machine learning and computer vision, further empower clinicians to deliver data-driven, personalized care tailored to the individual pathophysiology of each patient.

Despite these advances, the incorporation of AI into PUD management is accompanied by significant challenges that necessitate careful consideration. Among these, ethical issues, such as the safeguarding of patient data privacy and the mitigation of algorithmic bias, stand out as critical barriers to the equitable implementation of AI technologies. Algorithmic bias, if unaddressed, could disproportionately affect vulnerable populations and exacerbate healthcare disparities. Furthermore, the interpretability and transparency of AI models remain areas of concern, particularly when these tools are employed in high-stakes clinical decision-making. To foster trust among clinicians and patients, it is imperative to develop AI systems that are both explainable and robust.

Rigorous validation studies are another cornerstone for ensuring the safe and effective deployment of AI in clinical practice. Although preliminary studies have shown promising results in the use of AI for PUD management, larger, multicenter trials are essential to confirm these findings and establish the generalizability of AI applications. Such studies must be designed to evaluate not only the diagnostic accuracy and therapeutic efficacy of AI tools but also their impact on clinical workflows, cost-effectiveness, and patient satisfaction. The lack of standardized protocols for assessing AI performance further complicates these efforts, underscoring the need for consensus guidelines and regulatory frameworks to govern the development and evaluation of AI technologies in medicine.

Looking ahead, the future of AI in PUD management lies in the creation of interoperable systems that can seamlessly integrate with existing electronic health records (EHRs), diagnostic platforms, and therapeutic devices. Such integration will require close collaboration between clinicians, AI developers, and healthcare administrators to ensure that the resulting systems are user-friendly, reliable, and adaptable to the dynamic needs of diverse healthcare settings. Moreover, global initiatives aimed at democratizing access to AI technologies will be crucial for bridging the gap between resource-rich and resource-poor settings, thereby ensuring that the benefits of AI are equitably distributed. Training programs for healthcare professionals will also play a pivotal role in facilitating the adoption of AI, as clinicians must be equipped with the skills necessary to interpret AI outputs and integrate them into patient care effectively.

AI represents a powerful tool for transforming the management of complicated PUD, with the potential to enhance diagnostic precision, optimize therapeutic outcomes, and streamline clinical workflows. However, its successful integration into routine practice will require a multidisciplinary approach that addresses ethical, technical, and regulatory challenges. By fostering collaboration among stakeholders and prioritizing patient-centered care, the medical community can harness the transformative potential of AI to improve outcomes for patients with complicated PUD worldwide.

[1–15, 15–27]

Author details

[1]Kathmandu Institute of Technology, Teku Road, Kathmandu, 44600, Nepal. [2]Pokhara Digital University, Lakeside Street, Pokhara, 33700, Nepal. [3]Nepal Institute of Health, Birta Marg, Biratnagar, 56613, Nepal.

References

1. Lu, H., Robertson, D.H., Maeda, Y.: Gastric cancer: Advances in molecular pathology and targeted therapies. The Lancet Oncology **8**(7), 673–682 (2007)
2. Roberts, A.L., Wu, X.: Innovative therapies for inflammatory bowel disease: A review of clinical trials. In: Annual Meeting of the European Crohn's and Colitis Organization, pp. 95–102 (2017)
3. Parker, R.G., Khan, S.: Liver Disease: A Practical Approach to Diagnosis and Treatment. Mosby, Philadelphia (2004)
4. Zhang, X., Roberts, M.J.: Colorectal polyps: Risk stratification and management. Digestive Diseases and Sciences **62**(6), 1452–1461 (2017)
5. Chen, R., Meyer, L.K.: Liver regeneration: Cellular mechanisms and clinical applications. In: Proceedings of the World Hepatology Congress, pp. 45–52 (2014)
6. Harris, D.T., Sun, Z.: Clinical Gastroenterology: A Multidisciplinary Approach. CRC Press, Boca Raton, FL (2016)
7. Mendez, J.A., Tanaka, H.: Cirrhosis and portal hypertension: New perspectives on therapy. Hepatology International **3**(4), 245–255 (2005)
8. Zhang, H., O'Brien, M.J., Schmitt, G.: Liver transplantation in acute liver failure: A multicenter study. Liver Transplantation **12**(8), 1150–1160 (2006)
9. Andersson, E., Tan, W.-L.: Pancreatic cancer: Innovations in imaging and treatment. In: European Congress of Radiology, pp. 234–240 (2004)
10. Gadour, E., Hassan, Z., Gadour, R.: A comprehensive review of transaminitis and irritable bowel syndrome. Cureus **13**(7) (2021)
11. Nguyen, T.-M., Grüber, T.: Pancreaticobiliary maljunction: Diagnosis and treatment options. World Journal of Gastroenterology **22**(45), 9873–9885 (2016)
12. Smith, J.D., Lee, M.-S., Martínez, I.: Advances in the management of hepatocellular carcinoma. Journal of Hepatology **47**(3), 432–445 (2007)
13. Miller, D.R., Zhao, F.: The Digestive System: Pathologies and Clinical Practice. Oxford University Press, Oxford (2015)
14. Gadour, E., Hassan, Z., Hassan, A.: Y-shaped vesica fellea duplex gallbladder causing acute biliary pancreatitis. Cureus **13**(4) (2021)
15. Davies, H.P., Yang, J.-F.: Inflammatory Bowel Disease: Clinical Perspectives and Challenges. Wiley-Blackwell, Oxford, UK (2002)
16. Ramirez, L.A., Choi, S.-H.: Non-alcoholic steatohepatitis: Pathogenesis and emerging therapies. Nature Reviews Gastroenterology & Hepatology **6**(4), 315–325 (2009)
17. Miuțescu, B., Vuletici, D., Burciu, C., Turcu-Stiolica, A., Bende, F., Rațiu, I., Moga, T., Sabuni, O., Anjary, A., Dalati, S., *et al.*: Identification of microbial species and analysis of antimicrobial resistance patterns in acute cholangitis patients with malignant and benign biliary obstructions: a comparative study. Medicina **59**(4), 721 (2023)

18. Chen, J., Taylor, E.C., Kumar, A.: Cholangiocarcinoma: Advances in chemotherapy and radiotherapy. In: Proceedings of the World Congress of Gastrointestinal Oncology, pp. 78–86 (2014)
19. Abdelhameed, M., Hakim, O., Mohamed, A., Gadour, E.: Pattern and outcome of acute non-st-segment elevation myocardial infarction seen in adult emergency department of al-shaab teaching hospital: A prospective observational study in a tertiary cardiology center. Cureus **13**(9) (2021)
20. Miutescu, B., Vuletici, D., Burciu, C., Bende, F., Ratiu, I., Moga, T., Gadour, E., Bratosin, F., Tummala, D., Sandru, V., *et al.*: Comparative analysis of antibiotic resistance in acute cholangitis patients with stent placement and sphincterotomy interventions. Life **13**(11), 2205 (2023)
21. Brown, E.A., Wang, X.: Gastrointestinal Disorders: Diagnosis and Management. Springer, Berlin (2010)
22. Matsuda, Y., O'Brien, P.T.: Hepatitis b virus and liver cancer: An updated overview. Cancer Research **65**(12), 5721–5727 (2005)
23. Garcia, A.R., Singh, A., Müller, H.-P.: Autoimmune hepatitis: Pathogenesis and treatment options. Hepatology Research **27**(5), 381–392 (2003)
24. Wright, C.T., Zhou, W.: Endoscopic retrograde cholangiopancreatography in bile duct disorders. In: International Digestive Disease Forum, pp. 87–94 (2008)
25. Hassan, Z., Gadour, E.: Systematic review of endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage. Clinical Medicine **22**(Suppl 4), 14 (2022)
26. Martin, D.P., Chen, L., Johansson, E.: Endoscopic management of pancreatic pseudocysts: A retrospective analysis. In: International Conference on Gastroenterology, pp. 221–229 (2010)
27. Wang, Y., Clark, T.J.: Hepatobiliary imaging: Advances in mri techniques. Radiology **267**(2), 345–355 (2013)